[Federal Register Volume 65, Number 180 (Friday, September 15, 2000)]
[Notices]
[Page 55981]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 00-23798]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration


Antiviral Drugs Advisory Committee; Notice of Meeting

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

    This notice announces a forthcoming meeting of a public advisory 
committee of the Food and Drug Administration (FDA). The meeting will 
be open to the public.
    Name of Committee: Antiviral Drugs Advisory Committee.
    General Function of the Committee: To provide advice and 
recommendations to the agency on FDA's regulatory issues.
    Date and Time: The meeting will be held on October 16, 2000, 8:30 
a.m. to 5 p.m.
    Location: Marriott Washingtonian Center, the Ballrooms, 9751 
Washingtonian Blvd., Gaithersburg, MD.
    Contact Person: Nancy Chamberlin or Beverly O'Neil, Center for Drug 
Evaluation and Research (HFD-21), Food and Drug Administration, 5600 
Fishers Lane, (for express delivery, 5630 Fishers Lane, rm. 1093) 
Rockville, MD 20857, 301-827-7001, or by e-mail: 
[email protected], or FDA Advisory Committee Information Line, 
1-800-741-8138 (301-443-0572 in the Washington, DC area), code 12531. 
Please call the Information Line for up-to-date information on this 
meeting.
    Agenda: The committee will discuss the use of surrogate markers in 
the early development of immunomodulatory agents for the treatment of 
patients with human immunodeficiency virus (HIV).
    Procedure: Interested persons may present data, information, or 
views, orally or in writing, on issues pending before the committee. 
Written submissions may be made to the contact person by October 2, 
2000. Oral presentations from the public will be scheduled between 
approximately 1 p.m. to 2 p.m. Time allotted for each presentation may 
be limited. Those desiring to make formal oral presentations should 
notify the contact person before October 2, 2000, and submit a brief 
statement of the general nature of the evidence or arguments they wish 
to present, the names and addresses of proposed participants, and an 
indication of the approximate time requested to make their 
presentation.
    Notice of this meeting is given under the Federal Advisory 
Committee Act (5 U.S.C. app. 2).

    Dated: August 23, 2000.
Linda A. Suydam,
Senior Associate Commissioner.
[FR Doc. 00-23798 Filed 9-14-00; 8:45 am]
BILLING CODE 4160-01-F